ADAR1 Capital Management’s enGene Therapeutics ENGN Stock Holding History

ADAR1 Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.64M	Buy	2,104,986 +1,971,300	+1,475%	+$8.04M	0.17%	118
2026 Q1	$910K	Sell	133,686 -170,000	-56%	-$1.51M	0.05%	167
2025 Q4	$2.74M	Buy	+303,686	New	+$2.43M	0.2%	87
2025 Q3	–	Sell	-27,787	Closed	-$101K	–	236
2025 Q2	$101K	Buy	27,787 +3,988	+17%	+$15K	0.02%	175
2025 Q1	$107K	Buy	+23,799	New	+$148K	0.02%	163
2024 Q4	–	Sell	-1,970	Closed	-$13K	–	241
2024 Q3	$13K	Buy	1,970 +1,370	+228%	+$10.2K	﹤0.01%	250
2024 Q2	$5.66K	Buy	+600	New	+$7.7K	﹤0.01%	240

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ADAR1 Capital Management's ENGN Position: Q2 2026 in Review

ADAR1 Capital Management increased its enGene Therapeutics (ENGN) stake by 1,475% in Q2 2026, buying an estimated $8.04M and bringing the position to 2,104,986 shares worth $3.64M. The position accounts for 0.17% of the portfolio, ranked #118.

ADAR1 Capital Management first reported a position in ENGN in Q2 2024 and has held it in 7 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

ADAR1 Capital Management held 2,104,986 shares of enGene Therapeutics worth $3.64M as of Q2 2026.
ADAR1 Capital Management bought 1,971,300 enGene Therapeutics shares in Q2 2026, an estimated $8.04M.
enGene Therapeutics made up 0.17% of ADAR1 Capital Management's portfolio in Q2 2026, its #118 holding.
ADAR1 Capital Management first reported a position in enGene Therapeutics in Q2 2024 and has held it in 7 quarters since.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.